AI Summary
Thinking
Thinking
We reviewed 35 live results for yuflyma adalimumab aaty and narrowed them down to the 3 options that look most worth comparing first.
The options are Yuflyma (Adalimumab), Yuflyma and Yuflyma (adalimumab-aaty).
Source: Celltrion Healthcare
Description
Yuflyma is an adalimumab biosimilar, classified as a biologic Disease-Modifying Antirheumatic Drug (DMARD). It is used to treat immune-mediated inflammatory diseases by targeting and neutralizing TNF-alpha, helping to alleviate symptoms in conditions like psoriasis and arthritis.
Best for
psoriatic arthritis, inflammatory disease management and biologic DMARD users
Rate this product
Source: Celltrion Healthcare Singapore Private Limited
Description
Yuflyma is a high-concentration, citrate-free adalimumab biosimilar (referencing Humira) used for inflammatory conditions in Singapore. Its specialized formulation is designed to potentially reduce injection site pain for patients with rheumatoid arthritis and psoriasis.
Best for
high-concentration adalimumab, reduced injection pain preference and psoriasis management
Rate this product
Source: Celltrion USA, Inc.
Description
Yuflyma is a high-concentration (100 mg/mL), citrate-free, and latex-free biosimilar to Humira (adalimumab), classified as a TNF blocker. It is indicated for the treatment of various inflammatory conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Available in single-dose autoinjectors and prefilled syringes at strengths like 40 mg/0.4 mL and 80 mg/0.8 mL, this biologic medication offers room-temperature stability for up to 31 days, providing flexibility for autoimmune patient care.
Best for
rheumatoid arthritis treatment, citrate-free injection preference, Humira biosimilar seekers, Crohn's disease management and flexible storage needs
Rate this product
| Compare | #1Yuflyma (Adalimumab) | #2Yuflyma | #3Yuflyma (adalimumab-aaty) |
|---|---|---|---|
| Source | Celltrion Healthcare | Celltrion Healthcare Singapore Private Limited | Celltrion USA, Inc. |
| Description | Yuflyma is an adalimumab biosimilar, classified as a biologic Disease-Modifying Antirheumatic Drug (DMARD). It is used to treat immune-mediated inflammatory diseases by targeting and neutralizing TNF-alpha, helping to alleviate symptoms in conditions like psoriasis and arthritis. | Yuflyma is a high-concentration, citrate-free adalimumab biosimilar (referencing Humira) used for inflammatory conditions in Singapore. Its specialized formulation is designed to potentially reduce injection site pain for patients with rheumatoid arthritis and psoriasis. | Yuflyma is a high-concentration (100 mg/mL), citrate-free, and latex-free biosimilar to Humira (adalimumab), classified as a TNF blocker. It is indicated for the treatment of various inflammatory conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Available in single-dose autoinjectors and prefilled syringes at strengths like 40 mg/0.4 mL and 80 mg/0.8 mL, this biologic medication offers room-temperature stability for up to 31 days, providing flexibility for autoimmune patient care. |
| Best for | psoriatic arthritis, inflammatory disease management and biologic DMARD users | high-concentration adalimumab, reduced injection pain preference and psoriasis management | rheumatoid arthritis treatment, citrate-free injection preference, Humira biosimilar seekers, Crohn's disease management and flexible storage needs |
| Action | Celltrion Healthcare | Celltrion Healthcare Singapore Private Limited | Celltrion USA, Inc. |
| Rate this product |
"Yuflyma (Adalimumab) from Celltrion Healthcare."
TopFind picked this because Recognized by the HSA, Yuflyma offers a specialized biologic treatment path for patients with various autoimmune conditions in Singapore.
Note: TopFind AI compiles product and service information for general comparison purposes only.